The clinical program is done. The PDUFA date is set. What happens next determines whether the asset reaches its commercial potential — or spends the next 12 months fighting for payer access, building awareness from scratch, and managing access programs that weren’t designed for the actual patient population. Most pharma launches fail commercially, not scientifically. The difference is almost always in the 18 months before Day 1.
18 to 12 Months Out: Strategy and Infrastructure
Market access strategy finalized. Target payer segments identified. Formulary access goals — tiered by payer type and priority — are agreed upon before WAC is set, not after. The net price model is built with realistic rebate assumptions for the competitive landscape you’re entering.
HEOR package complete. Budget impact model, cost-effectiveness dossier, and real-world evidence plan developed. Payer value narrative tested with at least one major commercial plan and one PBM. If the economics don’t resonate now, they won’t resonate at formulary review.
Patient services model designed. Hub program structure, specialty pharmacy relationships, copay assistance program rules, and patient support infrastructure defined. Patient identification strategy — how you find the right patients before the Rx is written — built into the commercial model.
Competitive positioning locked. Your place in the treatment algorithm — relative to current SOC and anticipated competition — defined and stress-tested. Not aspirational positioning; honest positioning based on your label, your data, and the payer environment you’re entering.
12 to 6 Months Out: Commercial Build
Field force hired and trained. Not just headcount — territory alignment, targeting logic, and call plan built around your actual prescriber universe. Rare disease launches with 200-physician target lists require a fundamentally different field model than primary care launches. Build for your universe, not a generic template.
Medical Affairs pre-launch engagement underway. MSL territory assignments finalized. KOL relationships — particularly at the academic centers that will generate the real-world evidence and case studies that move community prescribers — active and advancing. Publication plan for any Phase 4 data aligned with launch timeline.
Payer contracting negotiations initiated. Major PBM and commercial plan negotiations cannot wait until after approval. Payer teams need to be in the room before the label is final, preparing for formulary placement under the most likely label scenario. Contracts need to be executable within weeks of approval, not months.
Label scenario planning complete. Three label scenarios modeled: best case, expected, and worst case. Commercial strategy for each scenario documented. The team needs to be able to pivot within 48 hours of approval without starting the commercial planning process over.
6 Months to Day 1: Execution Readiness
Distribution and channel set up. Specialty distributors, specialty pharmacies, and retail channel decisions finalized. 3PL relationships and inventory positioning confirmed. For injectable or infusion products, site-of-care strategy — hospital outpatient, infusion center, home infusion — decided and infrastructure in place.
Launch simulation run. End-to-end process from Rx written to drug in patient’s hands tested. Hub program tested with realistic case scenarios. Every exception path — prior auth denied, specialty pharmacy out of network, financial assistance application incomplete — has an owner and a resolution path.
Crisis plan exists. What happens if the label is narrower than expected? If a competitor gets approved the same week? If a safety signal emerges in the first 90 days? The teams that handle launch crises well are the ones that planned for them. The ones that don’t are the ones on the front page of trade press six months post-launch.
For related coverage on launch risk management and real-world execution, see our Commercial Launch Strategy Hub.
